Variant report
Variant | esv3322194 |
---|---|
Chromosome Location | chr4:103328029-103333627 |
allele | n/a |
Outlinks | Ensembl   UCSC |
- TF binding region (count:0)
- CpG islands (count:0)
- Chromatin interactive region (count:2)
- LncRNA region (count:0)
- Mature miRNA region (count: 0)
- miRNA target sites (count:0)
No data |
No data |
(count:2 , 50 per page) page:
1
No data |
No data |
No data |
No data |
No. | Variant name | Chromosome position | Chromatin state | Related regulatory elements | Target genes | Extended variants | Associated traits |
---|---|---|---|---|---|---|---|
1 | rs562050870 | chr4:103328062-103328063 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
2 | rs373082477 | chr4:103328099-103328100 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
3 | rs201232550 | chr4:103328102-103328103 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
4 | rs112655516 | chr4:103328120-103328121 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
5 | rs547894426 | chr4:103328157-103328158 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
6 | rs539688414 | chr4:103328160-103328161 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
7 | rs559544303 | chr4:103328179-103328180 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
8 | rs61373170 | chr4:103328189-103328190 | Weak transcription Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
9 | rs558329462 | chr4:103328202-103328203 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
10 | rs141109021 | chr4:103328210-103328211 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
11 | rs536926621 | chr4:103328262-103328263 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
12 | rs571224475 | chr4:103328322-103328323 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
13 | rs181932289 | chr4:103328346-103328347 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
14 | rs149842012 | chr4:103328381-103328382 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
15 | rs534293027 | chr4:103328392-103328393 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
16 | rs145856488 | chr4:103328394-103328395 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
17 | rs369443777 | chr4:103328414-103328415 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
18 | rs55804949 | chr4:103328433-103328434 | Weak transcription Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
19 | rs540064082 | chr4:103328512-103328513 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
20 | rs556881905 | chr4:103328529-103328530 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
21 | rs558378230 | chr4:103328539-103328540 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
22 | rs375820246 | chr4:103328554-103328555 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
23 | rs555556636 | chr4:103328613-103328614 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
24 | rs58546232 | chr4:103328620-103328621 | Weak transcription | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
25 | rs115074457 | chr4:103328636-103328637 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
26 | rs573984272 | chr4:103328644-103328645 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
27 | rs74437757 | chr4:103328672-103328673 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
28 | rs73837204 | chr4:103328691-103328692 | Weak transcription | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
29 | rs533265639 | chr4:103328696-103328697 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
30 | rs544833171 | chr4:103328760-103328761 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
31 | rs563125684 | chr4:103328772-103328773 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
32 | rs530584308 | chr4:103328902-103328903 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
33 | rs116738567 | chr4:103328980-103328981 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
34 | rs567401133 | chr4:103328997-103328998 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
35 | rs148987625 | chr4:103329022-103329023 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
36 | rs4698852 | chr4:103329039-103329040 | Weak transcription | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
37 | rs138361221 | chr4:103329085-103329086 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
38 | rs7683109 | chr4:103329088-103329089 | Weak transcription | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
39 | rs11097779 | chr4:103329111-103329112 | Weak transcription | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
40 | rs570286216 | chr4:103329155-103329156 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
41 | rs72928344 | chr4:103329165-103329166 | Weak transcription | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
42 | rs556037738 | chr4:103329169-103329170 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
43 | rs574242014 | chr4:103329174-103329175 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
44 | rs112319914 | chr4:103329202-103329203 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
45 | rs553072494 | chr4:103329203-103329204 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
46 | rs578074929 | chr4:103329204-103329205 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
47 | rs545113641 | chr4:103329222-103329223 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
48 | rs375586551 | chr4:103329253-103329254 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
49 | rs562477893 | chr4:103329282-103329283 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
50 | rs533035540 | chr4:103329288-103329289 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
Disease | PMID | Source |
---|---|---|
Acute lymphoblastic leukemia | 22237106 | CNVD |
Glioblastoma multiforme | 21080181 | CNVD |
Esophageal squamous carcinoma | 21637470 | CNVD |
Chordoma | 21602918 | CNVD |
HIV/AIDS | 22032296 | CNVD |
Medulloblastoma | 21979893 | CNVD |
Neuroblastoma | 18923191 | CNVD |
Thoracic aortic aneurysm | 21092924 | CNVD |
Intellectual disability | 22102821 | CNVD |
Autism | 22495311 | CNVD |
Breast cancer | 21858162 | CNVD |
Small bowel adenocarcinoma | 21586687 | CNVD |
Gastric cancer | 21586687 | CNVD |
Basal cell lymphoma | 16317097 | CNVD |
Diffuse large b-cell lymphoma | 16317097 | CNVD |
Melanoma | 18172304 | CNVD |
Acute lymphoblastic leukemia | 20067559 | CNVD |
Breast cancer | 17603634 | CNVD |
Hepatocellular carcinoma | 16750200 | CNVD |
Myxofibrosarcoma | 16751306 | CNVD |
Esophageal squamous carcinoma | 18350619 | CNVD |
Breast cancer | 16272173 | CNVD |
Colorectal cancer | 19359472 | CNVD |
Malignant mesothelioma | 18160781 | CNVD |
Medulloblastoma | 18056178 | CNVD |
Multiple myeloma | 17077331 | CNVD |
Pleural malignant mesothelioma | 18160781 | CNVD |
Primary mediastinal b-cell lymphoma | 17728785 | CNVD |
Oral squamous cell carcinoma | 17134496 | CNVD |
4q-syndrome | 17576883 | CNVD |
Cancer | 21637783 | CNVD |
Non-syndromic sensorineural hearing loss | 18471307 | CNVD |
Colorectal cancer | 20709793 | CNVD |
Muscular dystrophy | 21149563 | CNVD |
Endometrial cancer | 22040021 | CNVD |
Breast cancer | 21264507 | CNVD |
Glioblastoma multiforme | 19960244 | CNVD |
Glioblastoma multiforme | 17387387 | CNVD |
Hepatocellular carcinoma | 22174799 | CNVD |
Liposarcoma | 21253554 | CNVD |
Oligodendroglial tumors | 17285580 | CNVD |
Cervical cancer | 21062161 | CNVD |
Metanephric adenoma | 20802469 | CNVD |
Breast cancer | 16608533 | CNVD |
Adenoid cystic carcinoma | 18698036 | CNVD |
Lung cancer | 19208797 | CNVD |
Wilms tumour | 21544195 | CNVD |
Breast cancer | 21785460 | CNVD |
Myelodysplastic syndrome | 21251322 | CNVD |
Lung cancer | 18438408 | CNVD |
Cancer | 22429812 | CNVD |
Acute lymphoblastic leukemia | 20435627 | CNVD |
Cancer | 21183584 | CNVD |
primary effusion lymphomas | 17116491 | CNVD |
small cell lung cancer | 20016488 | CNVD |
Splenic marginal zone lymphoma | 21957467 | CNVD |
Breast cancer | 17133270 | CNVD |
T-cell prolymphocytic leukemia | 19278963 | CNVD |
Colorectal cancer | 20459617 | CNVD |
High-grade prostatic intraepithelial neoplasia | 16573809 | CNVD |
Endometrioid adenocarcinoma | 16974079 | CNVD |
Congenital anomalies of the kidney and urinary tract | 20505237 | CNVD |
Breast cancer | 17393978 | CNVD |
Ovarian cancer | 21720365 | CNVD |
Hodgkin''s lymphoma | 17606441 | CNVD |
Esophageal cancer | 21851588 | CNVD |
Prostate cancer | 16573809 | CNVD |
Multiple myeloma | 16616336 | CNVD |
Melanoma | 20688739 | CNVD |
Breast cancer | 16397240 | CNVD |
Acute myeloid leukemia | 18000384 | CNVD |
Cutaneous T-cell lymphoma | 21881587 | CNVD |
Myelofibrosis | 22110671 | CNVD |
myeloid cancer | 21057493 | CNVD |
Non-syndromic sensorineural hearing loss | 17122850 | CNVD |
Pancreatic cancer | 17952125 | CNVD |
No. | Chromosome Location | Chromatin state | Cell line | Tissue |
---|---|---|---|---|
1 | chr4:103323400-103328400 | Weak transcription | Psoas Muscle | Psoas |
2 | chr4:103325000-103341600 | Weak transcription | H1 BMP4 Derived Mesendoderm Cultured Cells | ES cell derived |
3 | chr4:103325600-103328600 | Enhancers | Hela-S3 | cervix |
4 | chr4:103327400-103332200 | Weak transcription | Mesenchymal Stem Cell Derived Adipocyte Cultured Cells | ES cell derived |
5 | chr4:103328000-103328200 | Enhancers | Primary monocytes fromperipheralblood | blood |
6 | chr4:103328000-103332200 | Weak transcription | Monocytes-CD14+_RO01746 | blood |
7 | chr4:103328200-103332200 | Weak transcription | Primary monocytes fromperipheralblood | blood |
8 | chr4:103328400-103328600 | Enhancers | Psoas Muscle | Psoas |
9 | chr4:103328600-103332200 | Weak transcription | Hela-S3 | cervix |
10 | chr4:103332200-103332600 | Enhancers | Monocytes-CD14+_RO01746 | blood |
11 | chr4:103332200-103333400 | Enhancers | Mesenchymal Stem Cell Derived Adipocyte Cultured Cells | ES cell derived |
12 | chr4:103332200-103333600 | Enhancers | Adipose Derived Mesenchymal Stem Cell Cultured Cells | ES cell derived |
13 | chr4:103332200-103333600 | Enhancers | Primary monocytes fromperipheralblood | blood |
14 | chr4:103332200-103333600 | Enhancers | Hela-S3 | cervix |
15 | chr4:103332200-103333600 | Enhancers | NHDF-Ad | bronchial |
16 | chr4:103332400-103333000 | Enhancers | Primary neutrophils fromperipheralblood | blood |
17 | chr4:103332600-103333200 | Flanking Active TSS | Monocytes-CD14+_RO01746 | blood |
18 | chr4:103333000-103333600 | Enhancers | Foreskin Melanocyte Primary Cells skin03 | Skin |
19 | chr4:103333200-103333600 | Enhancers | Monocytes-CD14+_RO01746 | blood |
20 | chr4:103333400-103337800 | Weak transcription | Mesenchymal Stem Cell Derived Adipocyte Cultured Cells | ES cell derived |
21 | chr4:103333600-103334800 | Weak transcription | Hela-S3 | cervix |